A	A	DT	B-NP	O	
large	large	JJ	I-NP	O	
outbreak	outbreak	NN	I-NP	O	
of	of	IN	B-PP	O	
Salmonella	Salmonella	NNP	B-NP	O	
Paratyphi	Paratyphi	NNP	I-NP	O	
A	A	NNP	I-NP	O	
infection	infection	NN	I-NP	O	
among	among	IN	B-PP	O	
israeli	israeli	JJ	B-NP	O	
travelers	traveler	NNS	I-NP	O	
to	to	TO	B-PP	O	
Nepal	Nepal	NNP	B-NP	O	
.	.	.	O	O	

In	In	IN	B-PP	O	
Asia	Asia	NNP	B-NP	O	
,	,	,	O	O	
Salmonella	Salmonella	NNP	B-NP	O	
Paratyphi	Paratyphi	NNP	I-NP	O	
A	A	NNP	I-NP	O	
is	be	VBZ	B-VP	O	
an	an	DT	B-NP	O	
emerging	emerge	VBG	I-NP	O	
infection	infection	NN	I-NP	O	
,	,	,	O	O	
and	and	CC	O	O	
travelers	traveler	NNS	B-NP	O	
are	be	VBP	B-VP	O	
increasingly	increasingly	RB	B-ADVP	O	
at	at	IN	B-PP	O	
risk	risk	NN	B-NP	O	
.	.	.	O	O	

During	During	IN	B-PP	O	
October	October	NNP	B-NP	O	
2009-November	2009-November	NNP	I-NP	O	
2009	2009	CD	I-NP	O	
,	,	,	O	O	
an	an	DT	B-NP	O	
outbreak	outbreak	NN	I-NP	O	
in	in	IN	B-PP	O	
S	S	NN	B-NP	O	
.	.	.	O	O	

Paratyphi	Paratyphi	NNP	B-NP	O	
A	A	NNP	I-NP	O	
infection	infection	NN	I-NP	O	
was	be	VBD	B-VP	O	
noted	note	VBN	I-VP	O	
in	in	IN	B-PP	O	
Israeli	Israeli	JJ	B-NP	O	
travelers	traveler	NNS	I-NP	O	
returning	return	VBG	B-VP	O	
from	from	IN	B-PP	O	
Nepal	Nepal	NNP	B-NP	O	
.	.	.	O	O	

An	An	DT	B-NP	O	
outbreak	outbreak	JJ	I-NP	O	
investigation	investigation	NN	I-NP	O	
included	include	VBD	B-VP	O	
a	a	DT	B-NP	O	
standardized	standardized	JJ	I-NP	O	
exposure	exposure	NN	I-NP	O	
questionnaire	questionnaire	NN	I-NP	O	
admitted	admit	VBN	B-VP	O	
to	to	TO	B-PP	O	
all	all	DT	B-NP	O	
patients	patient	NNS	I-NP	O	
and	and	CC	O	O	
medical	medical	JJ	B-NP	O	
chart	chart	NN	I-NP	O	
abstraction	abstraction	NN	I-NP	O	
.	.	.	O	O	

Isolates	Isolate	NNS	B-NP	O	
were	be	VBD	B-VP	O	
tested	test	VBN	I-VP	O	
for	for	IN	B-PP	O	
antimicrobial	antimicrobial	JJ	B-NP	O	
susceptibility	susceptibility	NN	I-NP	O	
and	and	CC	O	O	
pulsed	pulsed	JJ	B-NP	O	
-	-	HYPH	I-NP	O	
field	field	NN	I-NP	O	
gel	gel	NN	I-NP	O	
electrophoresis	electrophoresis	NN	I-NP	O	
(	(	(	O	O	
PFGE	PFGE	NN	B-NP	O	
)	)	)	O	O	
.	.	.	O	O	

During	During	IN	B-PP	O	
1	1	CD	B-NP	O	
October	October	NNP	I-NP	O	
2009-30	2009-30	CD	I-NP	O	
November	November	NNP	I-NP	O	
2009	2009	CD	I-NP	O	
,	,	,	I-NP	O	
37	37	CD	I-NP	O	
Israeli	Israeli	JJ	I-NP	O	
travelers	traveler	NNS	I-NP	O	
returning	return	VBG	B-VP	O	
from	from	IN	B-PP	O	
Nepal	Nepal	NNP	B-NP	O	
were	be	VBD	B-VP	O	
diagnosed	diagnose	VBN	I-VP	O	
with	with	IN	B-PP	O	
S	S	NN	B-NP	O	
.	.	.	O	O	

Paratyphi	Paratyphi	NNP	B-NP	O	
A	A	DT	B-NP	O	
bacteremia	bacteremia	NN	I-NP	O	
.	.	.	O	O	

All	All	DT	B-NP	O	
37	37	CD	I-NP	O	
case	case	NN	I-NP	O	
isolates	isolate	NNS	I-NP	O	
had	have	VBD	B-VP	O	
an	an	DT	B-NP	O	
identical	identical	JJ	I-NP	O	
pattern	pattern	NN	I-NP	O	
on	on	IN	B-PP	O	
PFGE	PFGE	NN	B-NP	O	
,	,	,	O	O	
and	and	CC	O	O	
all	all	DT	B-NP	O	
were	be	VBD	B-VP	O	
nalidixic	nalidixic	JJ	B-NP	O	
acid	acid	NN	I-NP	O	
resistant	resistant	JJ	B-ADJP	O	
.	.	.	O	O	

Only	Only	RB	B-NP	O	
1	1	CD	I-NP	O	
food	food	NN	I-NP	O	
venue	venue	NN	I-NP	O	
was	be	VBD	B-VP	O	
frequented	frequent	VBN	I-VP	O	
by	by	IN	B-PP	O	
all	all	PDT	B-NP	O	
the	the	DT	I-NP	O	
outbreak	outbreak	JJ	I-NP	O	
cases	case	NNS	I-NP	O	
,	,	,	O	O	
with	with	IN	B-PP	O	
the	the	DT	B-NP	O	
largest	large	JJS	I-NP	O	
number	number	NN	I-NP	O	
of	of	IN	B-PP	O	
exposures	exposure	NNS	B-NP	O	
occurring	occur	VBG	B-VP	O	
around	around	IN	B-PP	O	
the	the	DT	B-NP	O	
Jewish	Jewish	NNP	I-NP	O	
New	New	NNP	I-NP	O	
Year	Year	NNP	I-NP	O	
.	.	.	O	O	

All	All	DT	B-NP	O	
patients	patient	NNS	I-NP	O	
recovered	recover	VBD	B-VP	O	
without	without	IN	B-PP	O	
complications	complication	NNS	B-NP	O	
.	.	.	O	O	

Time	Time	NN	B-NP	O	
to	to	TO	B-PP	O	
defervescence	defervescence	NN	B-NP	O	
in	in	IN	B-PP	O	
17	17	CD	B-NP	O	
patients	patient	NNS	I-NP	O	
treated	treat	VBN	B-VP	O	
with	with	IN	B-PP	O	
ceftriaxone	ceftriaxone	NN	B-NP	O	
and	and	CC	I-NP	O	
azithromycin	azithromycin	NN	I-NP	O	
combination	combination	NN	I-NP	O	
was	be	VBD	B-VP	O	
3.2	3.2	CD	B-NP	O	
days	day	NNS	I-NP	O	
(	(	(	O	O	
±	±	NN	B-NP	O	
1.7	1.7	CD	I-NP	O	
)	)	)	O	O	
,	,	,	O	O	
whereas	whereas	IN	O	O	
in	in	IN	B-PP	O	
13	13	CD	B-NP	O	
cases	case	NNS	I-NP	O	
treated	treat	VBN	B-VP	O	
with	with	IN	B-PP	O	
ceftriaxone	ceftriaxone	NN	B-NP	O	
monotherapy	monotherapy	NN	I-NP	O	
,	,	,	O	O	
the	the	DT	B-NP	O	
time	time	NN	I-NP	O	
to	to	TO	B-PP	O	
defervescence	defervescence	NN	B-NP	O	
was	be	VBD	B-VP	O	
6.6	6.6	CD	B-NP	O	
days	day	NNS	I-NP	O	
(	(	(	O	O	
±	±	NN	B-NP	O	
1.8	1.8	CD	I-NP	O	
;	;	:	O	O	
P	P	NN	B-NP	O	
<	<	SYM	B-NP	O	
.	.	.	I-NP	O	
001	001	CD	I-NP	O	
)	)	)	O	O	
.	.	.	O	O	

A	A	DT	B-NP	O	
point	point	NN	I-NP	O	
-	-	HYPH	B-NP	O	
source	source	NN	I-NP	O	
,	,	,	O	O	
"	"	''	O	B-protein	
Paratyphoid	Paratyphoid	NNP	B-NP	I-protein	
Mary	Mary	NNP	I-NP	I-protein	
"	"	''	O	I-protein	
-	-	HYPH	B-NP	O	
like	like	JJ	I-NP	O	
outbreak	outbreak	NN	I-NP	O	
was	be	VBD	B-VP	O	
identified	identify	VBN	I-VP	O	
among	among	IN	B-PP	O	
Israeli	Israeli	JJ	B-NP	O	
travelers	traveler	NNS	I-NP	O	
to	to	TO	B-PP	O	
Nepal	Nepal	NNP	B-NP	O	
.	.	.	O	O	

Combination	Combination	NN	B-NP	O	
Ceftriaxone	Ceftriaxone	NN	I-NP	O	
-	-	HYPH	B-NP	O	
Azithromycin	Azithromycin	NN	I-NP	O	
therapy	therapy	NN	I-NP	O	
may	may	MD	B-VP	O	
provide	provide	VB	I-VP	O	
a	a	DT	B-NP	O	
therapeutic	therapeutic	JJ	I-NP	O	
advantage	advantage	NN	I-NP	O	
over	over	IN	B-PP	O	
monotherapy	monotherapy	NN	B-NP	O	
,	,	,	O	O	
and	and	CC	O	O	
merits	merit	VBZ	B-VP	O	
further	further	JJ	B-NP	O	
clinical	clinical	JJ	I-NP	O	
trials	trial	NNS	I-NP	O	
.	.	.	O	O	

